



FOR IMMEDIATE RELEASE: March 27, 2025
Kirsten Krupps - Senior Product Marketing Manager
OriGen Biomedical, Inc.
k.krupps@origenbio.com
512-522-2343

ORIGEN BIOMEDICAL ANNOUNCES STRATEGIC PARTNERSHIP WITH BLOOD CENTERS OF AMERICA

AUSTIN, 27 MARCH 2025: OriGen Biomedical, a leading provider of cryopreservation and cell culture products, is pleased to announce a strategic partnership with Blood Centers of America (BCA), the largest blood supply network in the United States.

The partnership will provide the BCA Advanced Therapies network along with BCA's tissue center members with consistent access to OriGen Biomedical's high-quality cryopreservation medical devices, including cryobags and related products, which are crucial for the storage, transport, and manufacturing of biological materials in cell and gene therapy applications, as well as tissue recovery and tissue product manufacturing.

"We are excited to partner with Blood Centers of America to bring our innovative cryopreservation technologies to its network," said Tonia Wilson, Director of Global Business Development at OriGen Biomedical. "By working together, we aim to enhance the availability and quality of critical blood and cellular products, ultimately improving patient outcomes."

"As the landscape of advanced therapy continues to evolve and scale to larger commercial volumes, it is paramount for us to ensure our member organizations are equipped with reliable access to critical solutions to meet the demands of research, clinical, and commercial applications now and well into the future," said Sam Keith, SVP of Supply Chain and Business Development of Blood Centers of America. "OriGen Biomedical's expertise and product quality align perfectly with our commitment to supporting life-saving therapies."





BCA represents over 70 independent blood centers, tissue banks and advanced therapy organizations. BCA's blood center members supply over 50% of the nation's blood and provide essential support for hospitals, research institutions, and biotech companies. The partnership with OriGen will expand access to cutting-edge storage and cryopreservation solutions, further strengthening BCA's ability to meet the growing demand for blood and tissue products as well as cellular therapies.

OriGen Biomedical has a long-standing commitment to advancing medical technology and supporting the healthcare community with reliable and innovative products. The company's dedication to quality and patient safety makes it an ideal partner for BCA's mission-driven initiatives.

ABOUT ORIGEN BIOMEDICAL

OriGen Biomedical, Inc. is a leading producer of cryopreservation and cell culture products. Our focus is to produce a range of products to support the treatment of cancer, genetic conditions, and other life-threatening diseases. OriGen Biomedical® products are designed with the patient and user in mind and we strive to maintain excellent customer service to ensure that patient care is the priority. Quality is the foundation of all product designs at OriGen, and each product is produced with the intention that it will improve patient health. Founded in 1997 and headquartered in Austin, Texas, OriGen is certified annually to ISO 13485 standards and regularly inspected by the FDA, MDSAP, ISO certification organizations, and our customers. To learn more visit <u>origen.com</u> and follow us on <u>LinkedIn</u> and <u>X</u>.

ABOUT BLOOD CENTERS OF AMERICA (BCA)

Blood Centers of America (BCA) is the largest blood supply network in the United States. The BCA Advanced Therapies Network is a diverse, integrated portfolio offering a full spectrum of support for the development and delivery of advanced therapies. With the largest network of facilities in advanced therapies, their network brings unparalleled and coordinated access to a vast array of members and clients with a variety of service offerings related to starting material, testing, quality control, cryopreservation, manufacturing and clinical applications. To learn more, visit <u>bcaadvancedtherapies.com</u>.